Begoña Taboada Valladares*, Patricia Calvo Crespo, Urbano Anido Herranz, Antonio Gómez Caamaño
Valladares et al. J Clin Transl Res 2021; 7(2):12
Published online: April 16, 2021
Abstract
Background: Adjuvant treatment for both small-cell and non-small-cell lung cancer is a controversial topic. There are no published results from prospective studies that either confirm or reject the benefit of adjuvant radiotherapy, although the presentation of recent studies at a number of conferences questions whether there should be a change in the paradigm of adjuvant RT for lung cancer.
Aim: The main goal of this study is to review the most relevant publications on the topic, updating the state of the matter regarding adjuvant radiotherapy following lung surgery, and analyzing the role of chemotherapy in the process.
Relevance for patients: This review aims to assess the potencial benefit of PORT in NSCLC and SCLC patients by looking at recent research. In doing so, it will be posible to determine wich patients might benefit from it as adjuvant treatment after pulmonary resection.
DOI: http://dx.doi.org/10.18053/jctres.07.202102.012
Author affiliation
1. Radiation Oncology Department, Hospital Universitario Santiago de Compostela. Tr Choupana S/N, 15706 Santiago de Compostela, Spain.
2. Medical Oncology Department, Hospital Universitario Santiago de Compostela. Tr Choupana S/N, 15706 Santiago de Compostela, Spain.
*Corresponding autor
Begoña Taboada Valladares
Radiation Oncology Department, Hospital Universitario Santiago de Compostela. Tr Choupana S/N, 15706 Santiago de Compostela, Spain
Email: Maria.Begona.Taboada.Valladares@sergas.es
Handling editor:
Michal Heger
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China
Downloads
Full text PDF
Review process file (223.6 KB)
